Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals

被引:13
|
作者
Rozera, Gabriella [1 ]
Fabbri, Gabriele [2 ]
Lorenzini, Patrizia [2 ]
Mastrorosa, Ilaria [2 ]
Timelli, Laura [2 ]
Zaccarelli, Mauro [2 ]
Amendola, Alessandra [1 ]
Vergori, Alessandra [2 ]
Plazzi, Maria Maddalena [2 ]
Cicalini, Stefania [2 ]
Antinori, Andrea [2 ]
Capobianchi, Maria Rosaria [1 ]
Abbate, Isabella [1 ]
Ammassari, Adriana [2 ]
机构
[1] IRCCS, Natl Inst Infect Dis L Spallanzani, Lab Virol, Rome, Italy
[2] IRCCS, Natl Inst Infect Dis L Spallanzani, Clin Dept, Rome, Italy
来源
PLOS ONE | 2017年 / 12卷 / 10期
关键词
CD4(+) T-CELLS; INTERFERON-ALPHA; HIV-1-INFECTED PATIENTS; VIRUS-INFECTION; THERAPY; REPLICATION; PERSISTENCE; RESERVOIR; RALTEGRAVIR; DECAY;
D O I
10.1371/journal.pone.0187095
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Aim was to determine the dynamics of peripheral blood mononuclear cells (PBMC)-associated total HIV-1 DNA in successfully ART-treated HIV/HCV co-infected patients receiving DAA treatment and to explore possible virological hypotheses underlying the phenomenon. Methods Longitudinal, single-centre study measuring total HIV-1 DNA before the start of DAA, at the end of treatment (EOT), and 3 months after treatment. Univariable and multivariable analyses were used to assess factors associated with HIV-1 DNA increase >= 0.5 Log copies/million PBMC. Episomal 2-LTR forms, residual HIV-1 viremia and proviral DNA quasispecies evolution were also investigated. Results 119 successfully ART-treated HIV/HCV co-infected patients were included. Median baseline HIV-1 DNA was 3.84 Log copies/million PBMC (95% CI 3.49-4.05), and no significant variation with respect to baseline was found at EOT and after 3 months of DAA termination. In 17% of cases an increase >= 0.5 Log copies/million PBMC was observed at EOT compared to baseline. HIV-1 DNA increase was independently associated with lower baseline HIV-1 DNA, longer HIV suppression, raltegravir-based ART and previous exposure to interferon/ribavirin for HCV treatment. In none of the patients with HIV-1 DNA increase, 2-LTR forms were detected at baseline, while in 2 cases 2-LTR forms were found at EOT, without association with residual HIV-1 RNA viremia. No evidence of viral evolution was observed. Conclusions In successfully ART-treated HIV/HCV co-infected patients receiving DAA, PBMC-associated total HIV-1 DNA was quite stable over time, but some patients showed a considerable increase at EOT when compared to baseline. A significantly higher risk of HIV DNA increase was found, in presence of lower cellular HIV reservoir at baseline. Activation of replicative-competent virus generating new rounds of viral replication seems unlikely, while mobilization of cell-associated HIV from tissue reservoirs could be hypothesized.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals
    Rockstroh, Juergen K.
    LIVER INTERNATIONAL, 2015, 35 : 51 - 55
  • [2] Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals
    Hasson, Hamid
    Merli, Marco
    Messina, Emanuela
    Bhoori, Sherrie
    Salpietro, Stefania
    Morsica, Giulia
    Regalia, Enrico
    Bagaglio, Sabrina
    Lazzarin, Adriano
    Uberti-Foppa, Caterina
    Mazzaferro, Vincenzo
    JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 415 - 417
  • [3] Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals
    Saverio G. Parisi
    Samantha Andreis
    Monica Basso
    Silvia Cavinato
    Renzo Scaggiante
    Marzia Franzetti
    Massimo Andreoni
    Giorgio Palù
    Anna Maria Cattelan
    Medical Microbiology and Immunology, 2017, 206 : 419 - 428
  • [4] Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada
    Rana, Urvi
    Driedger, Matt
    Sereda, Paul
    Pan, Shenyi
    Ding, Erin
    Wong, Alex
    Walmsley, Sharon
    Klein, Marina
    Kelly, Deborah
    Loutfy, Mona
    Thomas, Rejean
    Sanche, Stephen
    Kroch, Abigail
    Machouf, Nima
    Roy-Gagnon, Marie-Helene
    Hogg, Robert
    Cooper, Curtis L.
    BMC INFECTIOUS DISEASES, 2019, 19 (01)
  • [5] Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada
    Urvi Rana
    Matt Driedger
    Paul Sereda
    Shenyi Pan
    Erin Ding
    Alex Wong
    Sharon Walmsley
    Marina Klein
    Deborah Kelly
    Mona Loutfy
    Rejean Thomas
    Stephen Sanche
    Abigail Kroch
    Nima Machouf
    Marie-Helene Roy-Gagnon
    Robert Hogg
    Curtis L. Cooper
    BMC Infectious Diseases, 19
  • [6] Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
    L. Dold
    C. Schwarze-Zander
    C. Boesecke
    R. Mohr
    B. Langhans
    J.-C. Wasmuth
    C. P. Strassburg
    J. K. Rockstroh
    U. Spengler
    Scientific Reports, 9
  • [7] Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals
    Parisi, Saverio G.
    Andreis, Samantha
    Basso, Monica
    Cavinato, Silvia
    Scaggiante, Renzo
    Franzetti, Marzia
    Andreoni, Massimo
    Palu, Giorgio
    Cattelan, Anna Maria
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2017, 206 (06) : 419 - 428
  • [8] Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
    Dold, L.
    Schwarze-Zander, C.
    Boesecke, C.
    Mohr, R.
    Langhans, B.
    Wasmuth, J-C
    Strassburg, C. P.
    Rockstroh, J. K.
    Spengler, U.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [9] Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
    Mohamed, Inas E. L-Khedr
    EL-Saeed, Kadry Mohamed
    Al-Sadik, Mahmoud Hassan
    Anwar, Christina Alphonse
    EGYPTIAN LIVER JOURNAL, 2021, 11 (01)
  • [10] Response to direct acting antivirals in vertically HIV/HCV co-infected youths
    Carrasco, I.
    Sainz, T.
    Frick, M. A.
    Jimenez de Ory, S.
    Montero, M.
    Gavilan, C.
    Falcon, M. D.
    Couceiro, J. A.
    Bernardino, J. I.
    Rubio, R.
    Bisbal, O.
    Guerrero, C.
    Aldamiz-Echevarria, M. T.
    Miralles, P.
    Berenguer, J.
    Navarro, M. L.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 48 - 48